Exosomal miR-1246 in serum as a potential biomarker for early diagnosis of gastric cancer

• Published in: International journal of clinical oncology 2020-01, Vol.25 (1), p.89-99
• Main Authors: Shi, Yuntao, Wang, Zhonghong, Zhu, Xiaojuan, Chen, Ling, Ma, Yilan, Wang, Jiayan, Yang, Xiaozhong, Liu, Zheng
• Format: Article
• Language: English
• Subjects: Adult; Bioinformatics; Biomarkers; Biomarkers, Tumor - blood; Biomarkers, Tumor - metabolism; Cancer Research; Diagnosis; Early Detection of Cancer; ELAV-Like Protein 1 - metabolism; Exosomes; Exosomes - genetics; Female; Gastric cancer; Gene expression; Humans; Male; Medicine; Medicine & Public Health; MicroRNAs - blood; MicroRNAs - metabolism; Middle Aged; miRNA; Oncology; Original Article; RNA-binding protein; ROC Curve; Stomach Neoplasms - blood; Stomach Neoplasms - genetics; Stomach Neoplasms - pathology; Surgical Oncology; Transmission electron microscopy; Tumor suppressor genes
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-019-01532-9

Background Gastric cancer (GC) patients are usually diagnosed in advanced stages which results in high mortality. This study aimed to identify novel circulating miRNAs as biomarkers for the early detection of GC. Methods Candidate miRNA was identified after integrated analysis of two Gene Expression Omnibus (GEO) datasets and clinical serum samples. Exosomes extracted were verified using transmission electron microscopy (TEM) and western blot. The expressions of miRNAs were tested through qRT-PCR. Receiver operating characteristic curve (ROC) analysis was used to explore the diagnostic utility of miRNAs. RNA pull-down assay was used to find RNA binding proteins (RBPs) which transport candidate miRNA into exosomes. Bioinformatics analysis of candidate miRNA was conducted using DAVID and Cytoscape. Results After integrated analysis of two GEO datasets, six circulating miRNAs were found to be consistently upregulated in GC patients. Then, qRT-PCR demonstrated that serum miR-1246 was the one with the largest fold change. Studies in vitro revealed that elevated serum miR-1246 was tumor-derived by being packaged into exosomes with the help of ELAVL1. Thereafter, we discovered that exosomal miR-1246 expressions in serum could differentiate GC patients with TNM stage I from healthy controls (HCs) and patients with benign diseases (BDs) with area under the curve (AUC) of 0.843 and 0.811, respectively. Bioinformatics analysis revealed miR-1246, as a tumor suppressor in GC, could regulate several signaling pathways. Conclusion Circulating exosomal miR-1246 was a potential biomarker for the early diagnosis of GC.